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The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2,            
emerged into a world being rapidly transformed by artificial intelligence (AI) based on big              
data, computational power and neural networks. The gaze of these networks has in recent              
years turned increasingly towards applications in healthcare. It was perhaps inevitable that            
COVID-19, a global disease propagating health and economic devastation, should capture           
the attention and resources of the world’s computer scientists in academia and industry. ​The              
potential for AI to support the response to the pandemic has been proposed across a wide                
range of clinical and societal challenges [1], including disease forecasting, surveillance and            
antiviral drug discovery. This is likely to continue as the impact of the pandemic unfolds on                
the world’s people, industries and economy but ​a surprising observation on the current             
pandemic has been the limited impact AI has had to date in the management of COVID-19​.                
This correspondence focuses on exploring potential reasons behind the lack of successful            
adoption of AI models developed for COVID-19 diagnosis and prognosis, in front-line            
healthcare services. We highlight the moving clinical needs that models have had to address              
at different stages of the epidemic, and explain the importance of translating models to              
reflect local healthcare environments. We argue that both basic and applied research are             
essential to accelerate the potential of AI models, and this is particularly so during a rapidly                
evolving pandemic. ​This perspective on the response to COVID-19, may provide a glimpse             
into how the global scientific community should react to combat future disease outbreaks             
more effectively. 
The evolving clinical need  
The clinical management of COVID-19 has spanned various stages including anticipation,           
early detection, containment, mitigation, together aiming towards eventual eradication [​2​].          
Each stage differs in its measured and actual disease prevalence, which directly impacts the              
availability of clinical resources, and over a matter of weeks, clinical priorities can fluctuate              
rapidly. Priorities may range from the provision of robust diagnoses, maintenance of infection             
control to ensuring availability of facilities for mechanical ventilation. Such rapid changes            
occuring in tandem with enhanced knowledge of virus behaviour and availability of            
supporting data, have meant that the outputs required of predictive AI models need to              
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constantly evolve. Accordingly, the AI models that are most urgently needed and which can              
be feasibly built are likely to be different at each epidemic stage. 
 
The anticipation and early detection stages: With a relatively low number of positive             
cases and many potentially asymptomatic cases during the early stages of the pandemic, a              
highly sensitive diagnostic AI model to detect COVID-19 would have been useful. The lack of               
pre-existing data from this new disease, meant the feasibility of building such new AI models               
to determine diagnosis or prognosis remains an open challenge, yet one that is of particular               
interest to an AI community focused on breaking the existing barriers between data domains              
using machine learning. Generalising AI models to unseen data (inference), to data coming             
from different distributions (domain adaptation, transfer learning) and to data with limited or             
no labels (semi- or unsupervised learning), e.g. [3], are all priority areas in the technical               
development of AI and such non-fully-supervised methods may benefit all the scenarios            
discussed. These early stages of a new disease have been described as overlooked periods              
in the general management of infectious diseases [​4​]. The AI community should design             
strategies and methodologies for rapid deployment in the event of future epidemic threats, to              
enable data collection, model training, testing and wide deployment to be as efficient as              
possible.  
 
The containment and mitigation stages: During the containment and mitigation of           
COVID-19, data have become increasingly available with the exponential growth of           
confirmed positive cases. During this time it is essential to rapidly curate sizable training data               
sets and develop stable, well-performing AI models that can respond to emerging clinically             
urgent needs, such as rapid, consistent patient triage at scale across a health service. 
 
Reverse transcription polymerase chain reaction (RT-PCR) tests via nasopharyngeal         
swabbing with nearly 100% specificity are considered the diagnostic ground-truth for           
COVID-19. However RT-PCR has limited negative predictive value with variable availability           
and diagnostic speed. Alternative methodologies for diagnosing COVID-19 include medical          
imaging techniques such as computed tomography (CT) and chest radiographs (CXR) [5].            
Some groups have also explored point-of-care ultrasound albeit with limitations. Driven by            
data availability, the focus of AI work in COVID-19 has centered on RT-PCR-labelled             
diagnostic models, e.g. [6], or the automated evaluation of clinical/imaging features, e.g. lung             
involvement on CT imaging [7]. ​Those developing AI-assisted diagnostic tools must           
recognise that very high diagnostic accuracies are required to demonstrate added value            
above and beyond existing clinical imaging and RT-PCR tests.  
 
It is also important to question which prognostic outcomes require greatest prioritisation            
during this period. The majority of existing AI models aim to predict hospitalisation and              
mortality, e.g. [8], using predictors such as age, gender, blood biomarkers, pre-existing            
co-morbidities and imaging [5]. ​In resource constrained clinical environments, there is great            
value in predicting resource consumption as a “surrogate” prognostic outcome, as a lack of              
personal protective equipment (PPE) for example can directly affect community prognoses           
[9]. Intuitive candidate outcome measures for AI models might include time spent on             
mechanical ventilators and/or within intensive care units. Yet as knowledge of COVID-19 has             
grown, early intubation of a patient has diminished in priority in the care pathway. Similarly,               
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with limitations in resources pragmatic choices have had to be made regarding patient             
selection for intensive care unit admission. Evolving management strategies such as these            
have a real-time impact on the outcomes that AI models aim to predict. Disease progression               
(or regression following treatment) models can be trained using time series data, such as              
longitudinal CT images [10], to quantify the likelihood of development of severe pneumonia             
and acute myocardial injury, two leading causes of mortality [​11​], and the cytokine release              
syndrome. A lesson from the COVID-19 pandemic has been that AI models motivated             
merely by the practical convenience of utilising acquiring labelled data have had limited             
clinical value.  
 
The eradication stage and beyond: ​At the later eradication stage, constraints in data             
availability, development time and clinical resources would gradually be eased. The number            
of positive cases can drop quickly. Yet the need for a real-time, convenient, highly-sensitive              
screening tool may persist to control transmission and judiciously recognise potential           
outbreaks.  
 
The requirements for prognostic tools may shift to the identification of patients at risk of               
developing long term sequelae such as pulmonary fibrosis. Indeed ​cardiopulmonary,          
neurological [​12​] and urological [13] damage are all being recognised following COVID-19            
infection. ​Given the potentially significant health service resource requirements that may           
result from ​long-term complications across large swathes of the population, the post-acute            
phase of COVID-19 will be a critical clinical research area, where AI models may play a                
central role.  
Translating AI models 
A typical AI translation workflow includes model development, model deployment and model            
adaptation (or model update). The COVID-19 AI research efforts have been concentrated            
primarily on new model development and the urgency brought about by the pandemic must              
not override the stringent requirements for clinical deployment [​14​]. Despite perceived time            
pressures, rigorous validation is key to ensuring that safety and efficacy are tested; models              
must be validated before initial deployment, continuously monitored and adapted, when           
implemented in local healthcare environments and as outcome likelihoods change due to            
evolving patient management strategies. Failing to adhere to such practice will impede            
translation and compromise the impact of AI on clinical needs. 
 
Pre-deployment validation: Recent COVID-19 AI models have been criticised for a lack of             
transparency in development and a high likelihood of bias towards nonrepresentative patient            
populations [5]. Data limitations in availability and quality can be the inherent cause of              
problems, for example validation data sets with unrealistically high numbers of control cases             
acquired during the beginning or extremely low numbers of control cases at the peak of the                
outbreak. These models are unlikely to be directly useful in all stages of the pandemic due to                 
potential bias.  
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Best practices in rigorous design and analysis of experiments should be adopted for AI              
model validation. In addition, model interpretation methods help to explain the reasoning of             
the predictions, e.g. [​15, 16​], and may also indicate when certain data-driven methods are              
unlikely to generalise [17]. Model transparency could also be key to addressing regulatory             
and ethical issues [​18, 19​]. 
 
Local adaptation: It is not uncommon to find that an AI model trained with data from one                 
healthcare centre, or even from multiple centres, does not generalise as well at a new               
centre. For example, the accuracy of chest x-ray detection represented by the area under              
the receiver operating characteristic curve, was significantly reduced from 0.93 in a            
multi-centre internal validation, to 0.82, on external validation data [17]. The pre-deployment            
external validation reduces the risk of this overfitting problem based on the assumption that              
the external data represent new local data. However, the local data are likely to have unique                
characteristics due to centre-specific acquisition features, equipment and protocols, all of           
which may have differing clinical constraints and requirements - the local healthcare            
environment [​20​]. Moreover, temporal differences in data may increase, adversely affecting           
model accuracy, as the demographic and immunity landscape and clinical practice shift            
between different stages of the epidemic [21]. AI models therefore should have a continuous              
monitoring and adaptation strategy to these changing data to maintain their predictive            
accuracy.  
 
Most proposed AI approaches for COVID-19 diagnosis/prognosis have so far been “locked”            
algorithms that do not facilitate future adaptation. Model adapting methods from other            
medical applications should be tested and integrated in these developments, such as            
transfer learning [​22​] and model retraining with a small local data set. Recently, the FDA has                
proposed a new approach to allow AI-based software to adapt and improve from real-world              
use [​23​], paving the regulatory pathway to address these local adaptation needs. 
Conclusion 
The COVID-19 pandemic has presented numerous challenges to virtually every section of            
society in all geographic locations. AI can be an enabling technology to support urgent              
clinical needs in disease diagnosis and prognosis but is reliant on appropriate infrastructure,             
data management and translational pathways. New international cross-disciplinary        
collaborations, carefully identifying time-course-and-region-dependent clinical actions in       
response to COVID-19 can benefit from scientifically sound AI model development,           
validation and deployment to support local healthcare providers. Safe and responsible           
translation is the only way for realising the promise for AI models to contribute in combating                
the current coronavirus pandemic, its aftermath and, potential future clustered outbreaks or            
comparable healthcare emergencies. 
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